Metabolite “Glues” Find a More Flexible Way to Attack Cancer Targets
Researchers have uncovered why certain designed small molecules—called metabolite glues—can lock a regulatory protein into a harmful complex, and they used that insight to engineer stronger versions. The work centers on PPAT, a key metabolic enzyme that can be inhibited by purine-related compounds only when a second factor, the nucleotide-sensing protein NUDT5, is present.
The study begins with a surprising observation: when the team modified a thiopurine-derived glue, attaching a larger benzylthio group to 6-TIMP, the molecule did not lose potency. Instead, 6-benzylTIMP preserved similar PPAT inhibition in the presence of NUDT5 and became roughly fivefold more potent when NUDT5 was absent—suggesting the binding interface can adapt beyond what was expected.
To understand the molecular basis for this adaptability, the authors solved cryo-EM structures of PPAT bound to the improved glue 6-benzylTIMP in complex with NUDT5. The new structure revealed that 6-benzylTIMP binds in nearly the same orientation as the previously studied 6-meTIMP, but the larger benzyl group forces a different set of interactions in PPAT’s hydrophobic pocket.
That re-tuning of local contacts triggers a structural disturbance near a loop region containing residues I422–E436. In the benzylTIMP complex, this loop shifts away from the ligand, and high-resolution cryo-EM density in that area becomes less defined—consistent with increased conformational flexibility.
Armed with this structural map, the team tested a strategy for making even better thiopurine glues. They noticed that the methylthio group of 6-meTIMP occupies a PPAT hydrophobic pocket not similarly engaged by AMP, implying that adding hydrophobic character could strengthen inhibition.
Following that logic, the researchers synthesized 6-ethylthioinosine-5′-monophosphate (6-etTIMP). Compared with 6-meTIMP, 6-etTIMP showed about threefold stronger PPAT inhibition in a manner that depended on the metabolite-glue interface, indicating that subtle chemical changes can translate into measurable biochemical performance.
Finally, the study evaluated therapeutic relevance in human leukemia–like cells. 6-etTIMP reduced viability in a dose-dependent manner, with cytotoxicity diminished in cells lacking NUDT5 and in glue-deficient NUDT5 mutants. Importantly, 6-etTIMP produced a larger gap between wild-type and ΔNUDT5 cells than 6-meTIMP, reflected in a more favorable selectivity index.
Overall, the results show that PPAT–NUDT5 metabolite-glue pockets can undergo marked conformational changes to accommodate bulky ligands without collapsing glue function. The work points to a practical route for upgrading decades-old chemotherapeutic scaffolds by engineering their shape and hydrophobicity to exploit protein flexibility.
Subject of Research: Metabolite glues for purine sensing and chemotherapeutic response
Article Title: Metabolite glues as a means of purine sensing and chemotherapeutic response
Article References: Witus, S.R., Kober, M.M., Roh, H. et al. Nature (2026). https://doi.org/10.1038/s41586-026-10790-3
DOI: https://doi.org/10.1038/s41586-026-10790-3
Keywords: metabolite glues, PPAT, NUDT5, cryo-EM, thiopurine, purine sensing, chemotherapeutic response
Tags: cancer target modulationchemotherapy response predictioncryo-EM structural analysisdrug design and engineeringmetabolic enzyme inhibitionmetabolite gluesnucleotide-sensing proteinsNUDT5 protein functionPPAT enzyme regulationprotein-ligand interactionspurine sensingsmall molecule inhibitors
